Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.

Conditions

Parkinson Disease

Interventions / Drugs

Lenrispodun Placebo

View on ClinicalTrials.gov ↗

Sponsor

ITCI

Intra-Cellular Therapies

Neuroscience

F29/100

Study Details

Enrollment132 participants

Primary Completion—

Lead SponsorIntra-Cellular Therapies, Inc.

Data Retrieved2026-04-11 04:18:13.264743+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.